Abstracts Archive - Page 1271 of 2607 - ACR Meeting Abstracts

Abstract Number: 1270 • 2018 ACR/ARHP Annual Meeting
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Sharon Dowell¹, Gail S. Kerr², Alvin F. Wells³, Richard Haddad⁴, Paul DeMarco⁵, Joyce Joseph⁶, Mercedes Quinones⁷, Shelby Hochberg⁸, Jennifer Ude⁹, Jim Huang¹⁰ and David Nashel⁶, ¹Division of Rheumatology, Howard University, Washington, DC, ²Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴The Hospital for Special Surgery, New York, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center, Washington, DC, ⁷Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center and Howard University, Washington, DC, ⁸Washington DC VA Medical Center and Howard University, Washinton, DC, ⁹Washington DC VA Medical Center and Howard University, Washington, DC, ¹⁰Medstar Health Research Institute, Hyattsville, MD
Background/Purpose: Hyperuricemia is common, and along with other comorbidities (CM), is increasing in prevalence. Though often asymptomatic, it is associated with subclinical urate deposition detectable…
Abstract Number: 1271 • 2018 ACR/ARHP Annual Meeting
Predictive Factors of Increased Vascular Stiffness in Patient with Gout and Hyperuricemia
WooSeong Jeong¹, Jinseok Kim², Joon Hyouk Choi³ and Byeongzu Ghang¹, ¹Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South), ²Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South), ³Division of Cardiology, Department of Internal Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Background: Gout is the most common form of inflammatory arthritis and its prevalence is increasing in more affluent countries in recent decades. Many studies…
Abstract Number: 1272 • 2018 ACR/ARHP Annual Meeting
Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach
Jessica Michaud¹ and Jenna Beatty², ¹Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, ²University of Kansas, kansas city, MO
Background/Purpose: Gout is the most common form of inflammatory arthritis.1 The cornerstone of treatment for gout is urate-lowering therapy (ULT), which in the U.S. includes…
Abstract Number: 1273 • 2018 ACR/ARHP Annual Meeting
What Did Patients from the US Think about Their Gout in 2017?
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: The impact of chronic gout and acute flares on daily activities is severely limiting. Yet only 40% of gout patients receive urate-lowering therapy (ULT),…
Abstract Number: 1274 • 2018 ACR/ARHP Annual Meeting
Atmospheric Temperature and the Incidence of Gout Flare: Data from the Korea Meteorological Association and National Health Insurance Service
Rina So¹, Min Jung Kim², Sang Hee Kim², Sung Hyouk Choi¹, Hyung-Jin Yoon¹ and Kichul Shin³, ¹Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Gout management is mainly focused on life style modification and proper medications. Of note, seasonal variation of gout flare was also implemented to be…
Abstract Number: 1275 • 2018 ACR/ARHP Annual Meeting
Dual-Energy CT for the Diagnosis of Gout: A Prospective Study in Patients with No Prior History of Gout
Mihaela Gamala¹, Johannes W. G. Jacobs², Suzanne Linn-Rasker³, Maarten Nix⁴, Ben Heggelman⁴, Pieternel Pasker⁵, Jacob van Laar⁶ and Ruth Klaasen³, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, Meander Medical Center Amersfoort, Amersfoort, Netherlands, ⁴Radiology, Meander Medical Center Amersfoort, Amersfoort, Netherlands, ⁵Meander Academy, Meander Medical Center Amersfoort, Amersfoort, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands
Background/Purpose: Gout is associated with joint damage, and increased cardiovascular morbidity, so to diagnose and treat gout early is important. However, joint aspiration and microscopy…
Abstract Number: 1276 • 2018 ACR/ARHP Annual Meeting
Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population
Anastasia Slobodnick¹, Virginia Pike², Michael Toprover¹ and Michael Pillinger¹, ¹Medicine/Rheumatology, NYU School of Medicine, New York, NY, ²Medicine/Rheumatology, New York Harbor VA Healthcare System, New York, NY
Background/Purpose: Previous studies suggest that patients with gout are at increased risk for developing diabetes.1 One possible explanation for this increased risk is the activation…
Abstract Number: 1277 • 2018 ACR/ARHP Annual Meeting
A Prospective Study Examining the Prevalence of CT Erosions in the Feet and Ankles of Patients with Gout Treated with Allopurinol
Chio Yokose¹, Yuqing Zhang², Nicola Dalbeth³, Jie Wei¹, Savvas Nicolaou⁴, Scott Baumgartner⁵, Jia Hu⁶, Maple Fung⁵ and Hyon K. Choi¹, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³University of Auckland, Auckland, New Zealand, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Formerly Ardea Biosciences, San Diego, CA, ⁶Heron Therapeutics, San Diego, CA
Background/Purpose: Gout is characterized by episodes of acute arthritis that are self-limiting. However, patients with gout can also develop tophi, bone erosions, joint deformity and…
Abstract Number: 1278 • 2018 ACR/ARHP Annual Meeting
Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout
Amara Shaukat¹, Anna Gosling¹, Matthew Bixley¹, Amanda Phipps-Green¹, Tanya J. Major¹, Murray Cadzow¹, Nicola Dalbeth², Lisa K. Stamp³, Elizabeth Matisoo-Smith¹, Jennie Harre Hindmarsh⁴, Leo .A.B. Joosten⁵, Tim Jansen⁶, Matthijs Janssen⁶, Anne-Kathrin Tausche⁷, Philip Riches⁸, Alexander So⁹, Mariano Andres¹⁰, Geraldine M. McCarthy¹¹, Fernando Perez-Ruiz¹², Michael Doherty¹³, Rosa Torres¹⁴, Tom W.J. Huizinga¹⁵, Rachel Knevel¹⁶, Fina Kurreeman¹⁷ and Tony R. Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ⁵Radboud University Medical Center, Nijmegen, Netherlands, ⁶VieCuri Medical Center, Venlo, Netherlands, ⁷Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ⁸University of Edinburgh, Edinburgh, United Kingdom, ⁹University of Lausanne, Lausanne, Switzerland, ¹⁰Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ¹¹Mater Misericordiae University Hospital, Dublin, Ireland, ¹²BioCruces Health Research Institute, Barakaldo, Spain, ¹³The University of Nottingham, Nottingham, United Kingdom, ¹⁴La Paz University Hospital, Madrid, Spain, ¹⁵Department of Rheumatology, LUMC, Leiden, Netherlands, ¹⁶Brigham and Women's Hospital, Boston, MA, ¹⁷Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Mitochondria execute roles in diverse cellular pathways. As a danger signal, damaged mitochondria can induce inflammation in response to stress through NLRP3 inflammasome activation,…
Abstract Number: 1279 • 2018 ACR/ARHP Annual Meeting
Relative Insufficiency of Renal Uric Acid Excretion in Gout Patients with Obesity Leads to High Serum and Glomerular Filtration Load of Uric Acid
Jin-Jian Liang, Qian-Hua Li, Ying-Qian Mo, Xiu-Ning Wei, Dong-Hui Zheng and Lie Dai, Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Gout is usually accompanied by metabolic diseases including obesity, hypertension, diabetes, and dyslipidemia. Obesity has been confirmed as a risk factor for gout. This study aims to explore…
Abstract Number: 1280 • 2018 ACR/ARHP Annual Meeting
Higher Body Fat Percentage in Non-Obese Late-Onset Gout Patients
Qian-Hua Li, Kui-Min Yang, Yan-Hui Xu, Xin-Yun Du, Jin-Jian Liang, Jian-Zi Lin, Ying-Qian Mo and Lie Dai, Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: There is a trend of younger gout onset related to higher obesity prevalence. BMI is limited to discriminate between fat and lean mass. Body…
Abstract Number: 1281 • 2018 ACR/ARHP Annual Meeting
Association of HFE Genotypes with Clinical Severity in Patients with Definite Calcium Pyrophosphate Arthritis
Fernando Perez-Ruiz^1,2,3 and Joana Atxotegi⁴, ¹BioCruces Health Research Institute, Barakaldo, Spain, ²Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ³University of the Basque Country (UPV/EHU), Bilbao, Spain, ⁴Rheumatology Division, Cruces University Hospital, Barakaldo, Spain
Background/Purpose: several metabolic disturbances that reduce the activity of pyrophosphatases have been associated with development of pyrophosphate arthritis (PPA), but there is scarce data on…
Abstract Number: 1282 • 2018 ACR/ARHP Annual Meeting
Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase
Brian F. Mandell¹, Naomi Schlesinger², N. Lawrence Edwards³, Anthony Yeo⁴ and Peter E. Lipsky⁵, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Rheumatology, University of Florida Health Science Center, Gainesville, FL, ⁴Horizon Pharma, Lake Forest, IL, ⁵AMPEL BioSolutions, Charlottesville, VA
INFLUENCE OF RENAL FUNCTION ON THE VELOCITY OF TOPHUS RESOLUTION AND ACHEIVEMENT OF DISEASE REMISSION IN PATIENTS WITH CHRONIC REFRACTORY GOUT TREATED WITH PEGLOTICASEBackground/Purpose: Impaired…
Abstract Number: 1283 • 2018 ACR/ARHP Annual Meeting
Calcium Pyrophosphate Crystal Deposition in a Cohort of 48 Patients with Gitelman Syndrome
Emilie Chotard¹, Anne Blanchard², Gilles Gailly¹, Rosa Vargas-Poussou³ and Hang-Korng Ea^4,5, ¹AP-HP, Hôpital Lariboisière, service de rhumatologie, centre Viggo Petersen, PARIS, France, ²AP-HP, Hôpital Européen Georges Pompidou, Service de néphrologie, PARIS, France, ³AP-HP, Hôpital Européen Georges Pompidou, Service de génétique, PARIS, France, ⁴AP-HP, Hôpital Lariboisière, service de rhumatologie, centre Viggo Petersen, Paris, France, ⁵INSERM UMR1132, Bioscar, University Paris Diderot, PARIS, France
Background/Purpose: Gitelman syndrome (GS) is a rare recessively inherited tubulopathy, caused by inactive mutations in SLC12A3 gene encoding the thiazide-sensitive-sodium-chloride transporter. It is characterized by…
Abstract Number: 1284 • 2018 ACR/ARHP Annual Meeting
Initial Pegloticase Serum Levels Predict Persistent Responsiveness in Patients with Chronic Refractory Gout
Kenneth Saag¹, Mitchell Feinman², Herbert S. B. Baraf³, Roy Fleischmann⁴, Arthur Kavanaugh⁵ and Peter E. Lipsky⁶, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²ACME Research, LLC, Orangeburg, SC, ³Arthritis and Rheumatism Associates, Wheaton, MD, ⁴Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite an initial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].